不可逆电穿孔联合树突状细胞疫苗治疗骨肉瘤。
Irreversible Electroporation Combined With Dendritic Cell-based Vaccines for the Treatment of Osteosarcoma.
机构信息
Department of Spinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, P.R. China.
Department of Radiological Sciences, University of California Irvine, Irvine, CA, U.S.A.;
出版信息
Anticancer Res. 2023 Aug;43(8):3389-3400. doi: 10.21873/anticanres.16514.
Osteosarcoma is the most common primary bone malignancy, and surgical resection combined with neoadjuvant chemotherapy is the gold-standard treatment for affected patients. Although the overall survival rates for patients with osteosarcoma currently range from 60% to 70%, outcomes remain disappointing for patients with recurrent, metastatic, or unresectable disease. Irreversible electroporation (IRE) is a novel ablation technique with the potential to elicit an immune response in solid tumors. Dendritic cell (DC)-based tumor vaccines have shown promising therapeutic efficacy in preclinical studies focused on osteosarcoma; however, only limited therapeutic efficacy has been observed in clinical trials. Thus, there is considerable potential therapeutic value in developing combination osteosarcoma treatments that involve IRE and DC-based tumor vaccines. In this review, we discuss recent advances in preclinical and clinical DC-based immunotherapies, as well as potential combinations of DC-based vaccines and IRE, that may improve therapeutic outcomes for patients with osteosarcoma.
骨肉瘤是最常见的原发性骨恶性肿瘤，手术切除联合新辅助化疗是此类患者的标准治疗方法。尽管目前骨肉瘤患者的总体生存率在 60%至 70%之间，但对于复发、转移或不可切除的疾病患者，治疗结果仍然不尽如人意。不可逆电穿孔（IRE）是一种新的消融技术，具有在实体瘤中引发免疫反应的潜力。基于树突状细胞（DC）的肿瘤疫苗在针对骨肉瘤的临床前研究中显示出了有前景的治疗效果；然而，在临床试验中仅观察到有限的治疗效果。因此，在开发涉及 IRE 和基于 DC 的肿瘤疫苗的联合骨肉瘤治疗方法方面具有相当大的潜在治疗价值。在这篇综述中，我们讨论了基于 DC 的免疫疗法的最新临床前和临床进展，以及基于 DC 的疫苗和 IRE 的潜在联合应用，这可能改善骨肉瘤患者的治疗结果。
Zotero 插件